Non-alcoholic steatohepatitis or NASH is a common term for “silent” liver disease. It resembles alcoholic liver disease, but occurs in people who drink little or no alcohol. The major feature in NASH is fat in the liver, along with inflammation and damage. Most people with NASH feel well and are not aware that they have a liver problem. Nevertheless, NASH can be severe and can lead to cirrhosis, in which the liver is permanently damaged and scarred and no longer able to work properly.
There are two main types of fatty liver disease: alcohol-related fatty liver disease and non-alcoholic fatty liver disease (NAFLD). NASH is also associated with lysosomal acid lipase deficiency. Patients with only steatosis but no fibrosis can progress to NASH. NASH itself can remain asymptomatic for years, or it can progress to cirrhosis and hepatocellular carcinoma. Risk factors such as insulin resistance related to obesity are central to the pathogenesis of NASH. Methods to diagnose NASH include MRI, CT or X-rays, however, only liver biopsy is reliable. There are no approved NASH drugs available in the market, but they are expected to enter the market by 2020. The potential NASH drug candidate include Elafirbranor, OCA, CVC and Aramchol. Currently, off-label drugs and therapies are employed to counter the progression of NASH.
The global NASH drugs market is expected to experience robust growth post the launch of NASH therapeutic drugs, primarily due to increasing patient base, rise in obese population, increasing number of people suffering from type-2 diabetes coupled with increasing healthcare expenditure. However, the market growth is hindered by the unavailability of effective biomarkers, high cost of drugs and undefined pathogenesis.
The report “Global NASH Drugs Market: Industry Analysis & Outlook (2016-2020)” analyzes the development of this market, with focus on the US and Europe markets. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: Genfit SA, Intercept Pharmaceuticals, Inc., Tobira Therapeutics Inc. and Galmed Pharmaceuticals Ltd. are being profiled along with their key financials and strategies for growth. The report contains a comprehensive analysis of the global NASH market along with the study of the regional markets.
Make an enquiry before buying this Report
Please fill the enquiry form below.